A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
NCT04699630
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
121
Enrollment
OTHER
Sponsor class
Conditions
Metastatic Breast Cancer
Locally Advanced Breast Cancer
Interventions
DRUG:
U3-1402
Sponsor
SCRI Development Innovations, LLC
Collaborators
[object Object]